언어선택 ENG
전체메뉴

History

Innovative Medicines based on
ImmunoModulatory Biologics

Global biotechnology company
that benefits the world

연혁
2021
08
Completion of 13 Bil. KRW Series A Funding by KB, Atinum, Partners, IMM and Timewise investment firms
04
Completion of the trademark application
03
Approval of the LMO facility
03
The 1st annual shareholder meeting
02
Certification of the venture company
01
Completion of 4 Bil. KRW Seed Funding led by KB investment and Atinum investment
2020
12
Certification of the company-affiliated research institute
11
Relocation of the HQ and the research institute to Gwanggyo Central Biz Tower
11
Worldwide exclusive in-licensing agreement for OXTIMA(IMB-101) with HK inno.N
10
Patent application for the IMB platform technology
09
Temporary research institute established at Gyeonggi Bio Center
08
Establishment of IMBiologics Inc.